Professional Documents
Culture Documents
ANTIINFECTIVE AGENTS
BY: ABDUL HAFIZ M. PITAMANAN, RN
OBJECTIVES:
PATHOPHYSIOLOGY
BACTERIA
• Known as prokaryotes
• Are single-celled organisms lacking a true nucleus
and nuclear membrane.
• Most have a rigid cell wall, and the structure of the
cell wall determines its shape.
• Reproduce by cell division about every 20minutes
• Produce toxins that cause cell lysis (cell death).
• Produce the enzyme beta-lactamase , which destroy
beta-lactam antibiotics such as penicillins and
cephalophorins.
HOW TO CLASSIFY
1. MICROSCOPIC USE
Identifies appearance or shape
Eg:
bacillus= rod shaped
cocci= spherical
staphylococci= cocci arranged in clusters
stretococci= cocci arranged in chains
GRAM-POSITIVE GRAM-NEGATIVE
• Staphylococcus aureus • Neisseria meningitides
• Streptococcus • E. Coli
pneumoniae • Haemophilus
• Group B. streptococcus Influenzae
• Clostridium perfringens
ANTIBACTERIAL
DRUGS/ANTIBIOTICS
• Are substances that inhibit bacterial growth
(bacteriostatic action) or kill bacteria and
other microorganisms (bactericidal action)
• Technically refers to the chemicals
produced by one kind of microorganisms
that inhibits the growth of or kills another.
• Do not act alone in destroying bacteria. (natural
body defenses or surgical procedures of infected wound and dressing)
ANTIBACTERIAL
DRUGS/ANTIBIOTICS
• Are obtained from natural sources or
manufactured.
Example: moldy bread on wounds to fight
infection
1928, a British bacteriologist named
Alexander Fleming discovered penicillin
when he noticed that mold contaminating
his bacterial cultures and inhibiting bacterial
growth.
That mold was called Penicillium notatum.
MECHANISMS OF ANTIBACTERIAL
ACTION
• TREATMENT OF CHOICE:
Vancomycin (Cancocin)
Other tx:
Linezolid (Zyvox)
Daptomycin (Cubicin)
Trimethoprim/sulfamethoxazole (Bactrim)
Doxycycline (Vibramycin)
Clindamycin (cleocin)
Telavancin (Vibativ)
VANCOMYCIN-RESISTANT
ENTEROCOCCUS FAECIUM (VREF)
• Another big resistance problem
• Resistant to penicillin, ampicillin gentamycin,
streptomycin, and vancomycin.
• Caused deaths in many persons with weakened immune
system
• Antibiotic susceptibility
• Performed to ascertain the effect of antibacterial drugs
have or specific organism.
• Detects the infective microorganisms present in a
sample (blood, sputum, swab) and what drug can kill
it.
Multiantibiotic therapy
• daily use of several antibiotic
• Delays the development of microorganisms resistance.
GENERAL ADVERSE REACTIONS TO
ANTIBIOTICS
Eg.
Dicloxacillin= oral antibiotic
Nafcillin and oxacillin= IM and IV preparations
EXTENDED –SPECTRUM PENICILLINS
(ANTIPSEUDOMONAL PENICILLINS)
• Broad-spectrum penicillins
• Effective against Pseudomonas aeruginosa,
a gram-negative bacillus that is difficult to
eradicate.
• Useful against many gram-negative
organisms such as Proteus spp., Serratia spp.,
Klebsiela pneumoniae, enterobacter spp.,
and Acinetobacter spp.
• Not penicillinase-resistant
• Similar pharmacologic action with
aminoglucosides but less toxic.
BETA-LACTAMASE INHIBITORS
3 Beta-lactamase inhibitors
1. Clavulanic acid (oral use)
2. Sulbactam (parenteral )
3. Tazobactam (parenteral)
• SUPERINFECTION
• occurrence of a
secondary infection when
the flora of the is disturbed.
BETA-LACTAMASE INHIBITORS;
PHARMACOKINETICS
• Amoxicillin
• well absorbed from the GI tract
• 20% protein bound
• 60% is excreted in the urine
• Dicloxacillin
• partially absorbed
• Highly protein-bound (95%)
• Excreted in the bile and urine
• If added with other highly protein-bound drugs, drug toxicity
may occur.
• Both have short half-lives.
BETA-LACTAMASE INHIBITORS;
PHARMACODYNAMICS
• Bactericidal
• Interferes bacterial cell-wall synthesis---cell lysis.
• Amoxicillin or dicloxacillin + probenecid (uricosuric drug- treat
gout) = increased antibacterial serum levels
MANAGEMENT RATIONALE
• Monitor renal funcion • Mostly excreted via the
of older adults. kidneys
• BUN, crea= if with
decreased renal function,
dose should be
decreased.
• Monitor closely during • Allergic reaction occurs
the first dose and in 5% to 10% op people
subsequent doses of receiving penicillin
penicillin. compounds.
BETA-LACTAMASE INHIBITORS;
DRUG INTERACTIONS
• Broad-spectrum penicillins-amoxicillin
and ampicillin--- may decreace the
effectiveness of oral contraceptives
• Potassium supplements + potassium
pen. G and V = increasing potassium
serum levels
• Penicillin + aminoglycosides in IV
solution= both drugs are inactivated
CEPHALOSPORINS
• CEPHALOSPORIM ACREMONIUM
• Discovered in seawater at a sewer outlet off the coast of
Sardinia in 1948
• Active against gram-positive and gram-negative bacteria
and resistant to beta lactamase.
• ERYTHROMYCIN
• The first macrolide
• Derived from the funguslike bacteria Streptomyces erytheus
• First introduced in the early 1950s.
• Acid-resistant salts are added to decrease the dissolution in
the stomach because the drug is destroyed by gastric acid
in the stomach------this allows the drug to be absorbed in
the intestines.
• Drug of choice for the treatment of mycoplasmal
pneumonia and Legionnaire’s disease (atypical neumonia)
• Should not be taken with clindamycin or incomycin
because they compete for receptor sites.
• Increase eryhtromycin blood concentration and risk of
sudden cardiac death when given with verapamil (Calan),
diltiazem (Cardizem), clarithromycin (Biaxin), fluconazole
(Diflucan), ketoconazole (Nizoral), itraconazole (Sporanox).
MACROLIDES
AZITHROMYCIN
CLARITHROMYCIN (BIAXIN) (ZITHROMAX)
• Side effects • Long half-life of up to
• Nausea 40-68hours----only
• Diarrhea prescribed once a day
• Abdominal discomfort for 5days.
• Frequently prescribed
for URTI and LRTI, STI’s,
and uncomplicated
skin infection.
LINCOSAMIDES
• VANCOMYCIN (VANCOCIN)
• Bactericidal
• Widely used in the 1950s to treat staphylococcus
infections
• Is used against drug-resistant S. aures and in
cardiac surgical prophylaxis for individuals with
penicillin allergies
• Has become ineffective for treating enterococci--
-resistance (VREF)---can cause staphylococcal
endocarditis and life threatening----treatment:
Quinupristin/dalfopristin
GLYCOPEPTIDES
• TELEVANCIN (VIBATIV)
• Treats selected gram-positive bacteria and skin infections.
• Semisynthetic derivative of vancomycin, with bactericidal
action against MRSA.
• Has an advantage of once-daily dosing.
GLYCOPEPTIDES;
PHARMACOKINETICS
• VANCOMYCIN
• Given orally for S. enterocolitis and antibioti-associated
pseudomembranous colitis due to Clostridium difficile.
• Not absorbed systematically when given orally and is
excreted in the feces.
• Given IV for severe infections due to MRSA; septicemia; and
bone, skin, LRT infections that do not respond or are resistant
to anibiotics.
• Intermittent vancomycin doses should be diluted in 100ml
for 500mg and 200ml for 1g of D5W, NS, or LR at a rate of
10mg/min or a min. of 60 mins.
• Excreted in the urine when given IV.
• 30% protein-bound
• Half-life is 6hours.
GLYCOPEPTIDES;
PHARMACODYNAMICS
• VANCOMYCIN
• Inhibits bacterial cell wall synthesis and is active
against several gram-positive microorganism.
• Peak action- 30mins after the end of the infusion.
GLYCOPEPTIDES
ADVERSE EFFECTS
SIDE EFFECTS • NEPHROTOXICITY
• Chills • OTOTOXICITY
• Auditory damage- permanent
• Dizziness hearing loss
• Vestibular branch damage
• Fever (cranial nerve VIII)- temporary
or permanent loss of balance
• Rashes • “red man” syndrome or red
• Nausea neck syndrome- red blotching
of the face, neck, and chest---
• Vomiting toxic effect due to rapid IV
injection
• Thrombophlebitis at the • Eosinophilia, neutropenia, and
injection site Stevens-Johns syndrome,
severe hypotension,
tachycardia, generalized
tingling, and rarely cardiac
arrest
GLYCOPEPTIDES;
DRUG INTERACTIONS
• Vancomycin + dimenhydrinate (Dramamine)=
masking of ototoxicity
• Vancomycin + furosemide, aminoglycosides,
amphotericin B, colistin, cisplatin, and cyclosporine=
Potentiated nephrotoxicity and ototoxicity
• Vancomycin + methotrexate ---inhibits
methotrexate excretion---methotrexate toxicity
• Oral vancomycin + cholestyramine colestipol---
decreased absorption of vancomycin
KETOLIDES
Telithromycin (Ketek)
• Is used for adults 18years of age and older to treat mild to
moderate community-acquired pneumonia that are usually
caused by Streptococcus pneumoniae and Haemophilus
influenza.
KETOLIDES
• PHARMACOKINETICS • PHARMACODYNAMICS
• Telithromycin is given PO • Inhibits protein synthesis in
and is well absorbed by microorganisms by
the GI tract and not binding to the bacterial
affected by food intake ribosomal RNA site of the
• Excreted in the feces and 50S subunit---bacterial
urine cell death.
• 60%-70% protein bound • Peak action is 1hour
• Half-life: 10hours
KETOLIDES;
DRUG INTERACTIONS
• Telithromycin + antilipidemics (simvastatin, lovastatin, and
atorvastatin), itraconazole, ketoconazole, benzodiazipines=
increase trlithromycin levels
• + Class 1A or class III antidysrhythmics= may lead to life
threatening dysrhythmias
• Telithromycin + rifampin, phenytoin, carbamazepine, or
phenobarbital= subtherapeutic effect; decreased
telithromycin blood levels
• Telithromycin x cisapride and pimozide= toxicity of the two
drugs
• Telithromycin + digoxin, metoprolol, midazolam, ritonavir
sirolimus, and tacrolimus= increase levels of the 5 drugs
• Telithromycin + ergot alkaloid derivatives antimigraine = ergot
toxicity (severe peripheral vasospasm and impaired
sensation).